bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Data 3 & 4 from Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer—Results from Phase Ib Trial IMU.ACS.001
Authors: Wiedermann Ursula , Garner-Spitzer Erika , Chao Yee , Maglakelidze Marina , Bulat Iurie , Dechaphunkul Arunee , Arpornwirat Wichit , Charoentum Chaiyut , Yen Chia-Jui , Yau Thomas Cheung , Tanasanvimon Suebpong , Maneechavakajorn Jedzada , Sookprasert Aumkhae , Bai Li-Yuan , Chou Wen-Chi , Ungtrakul Teerapat , Drinic Mirjana , Tobias Joshua , Zielinski Christoph C. , Chong Leslie , Ede Nicholas J. , Marino Mark T. , Good Anthony J.
Published: April 2023

Supplementary Data 3 & 4
Figure S3 from An Open-Source, Automated Tumor-Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer
Authors: Bai Yalai , Cole Kimberly , Martinez-Morilla Sandra , Ahmed Fahad Shabbir , Zugazagoitia Jon , Staaf Johan , Bosch Ana , Ehinger Anna , Nimeus Emma , Hartman Johan , Acs Balazs , Rimm David L.
Published: April 2023

Validation of QuPath TIL algorithms in TMA Yale2
Supplementary Data from Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia
Authors: Smith Catherine C. , Viny Aaron D. , Massi Evan , Kandoth Cyriac , Socci Nicholas D. , Rapaport Franck , Najm Matthieu , Medina-Martinez Juan S. , Papaemmanuil Elli , Tarver Theodore C. , Hsu Henry H. , Le Mai H. , West Brian , Bollag Gideon , Taylor Barry S. , Levine Ross L. , Shah Neil P.
Published: April 2023

Table S2
Figure S2 from Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial
Authors: Li Dapeng , Chi Yihebali , Chen Xiaohong , Ge Minghua , Zhang Yuan , Guo Zhuming , Wang Jun , Chen Jie , Zhang Jiewu , Cheng Ying , Li Zhendong , Liu Hui , Qin Jianwu , Zhu Jingqiang , Cheng Ruochuan , Xu Zhengang , Zheng Xiangqian , Tang Pingzhang , Gao Ming
Published: April 2023

Correlation between the percentage changes in calcitonin levels and in the sum of longest diameters of target lesions from baseline to week 6
Figure S1 from ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer
Authors: Mehrvarz Sarshekeh Amir , Alshenaifi Jumanah , Roszik Jason , Manyam Ganiraju C. , Advani Shailesh M. , Katkhuda Riham , Verma Anuj , Lam Michael , Willis Jason , Shen John Paul , Morris Jeffrey , Davis Jennifer S. , Loree Jonathan M. , Lee Hey Min , Ajani Jaffer A. , Maru Dipen M. , Overman Michael J. , Kopetz Scott
Published: April 2023

Supplementary Fig S1: Mutation Map of ARID1A gene in microsatellite-stable colorectal cancer patients.
Supplementary Data from Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors
Authors: Curigliano Giuseppe , Gelderblom Hans , Mach Nicolas , Doi Toshihiko , Tai David , Forde Patrick M. , Sarantopoulos John , Bedard Philippe L. , Lin Chia-Chi , Hodi F. Stephen , Wilgenhof Sofie , Santoro Armando , Sabatos-Peyton Catherine A. , Longmire Tyler A. , Xyrafas Alexandros , Sun Haiying , Gutzwiller Sabine , Manenti Luigi , Naing Aung
Published: April 2023

Supplementary Materials
Supplementary Figure S4 from Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients
Authors: Zaccaria Gian Maria , Bertamini Luca , Petrucci Maria Teresa , Offidani Massimo , Corradini Paolo , Capra Andrea , Romano Alessandra , Liberati Anna Marina , Mannina Donato , de Fabritiis Paolo , Cascavilla Nicola , Ruggeri Marina , Mina Roberto , Patriarca Francesca , Benevolo Giulia , Belotti Angelo , Gaidano Gianluca , Nagler Arnon , Hájek Roman , Spencer Andrew , Sonneveld Pieter , Musto Pellegrino , Boccadoro Mario , Gay Francesca
Published: April 2023

Figure S4. Landmark analysis (landmark point at 18 months) of OS (A, C) and PFS2 (B, D) in patients with multiple myeloma stratified according to ER18
Supplementary Figures from Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Authors: De Angelis Carmine , Fu Xiaoyong , Cataldo Maria Letizia , Nardone Agostina , Pereira Resel , Veeraraghavan Jamunarani , Nanda Sarmistha , Qin Lanfang , Sethunath Vidyalakshmi , Wang Tao , Hilsenbeck Susan G. , Benelli Matteo , Migliaccio Ilenia , Guarducci Cristina , Malorni Luca , Litchfield Lacey M. , Liu Jiangang , Donaldson Joshua , Selenica Pier , Brown David N. , Weigelt Britta , Reis-Filho Jorge S. , Park Ben H. , Hurvitz Sara A. , Slamon Dennis J. , Rimawi Mothaffar F. , Jansen Valerie M. , Jeselsohn Rinath , Osborne C. Kent , Schiff Rachel
Published: April 2023

Supplementary Figure S1. ER, PR, and HER2 mRNA and protein levels across endocrine-sensitive (parental) and endocrine-resistant BC cell lines. Supplementary Figure S2. Reduced sensitivity to CDK4/6 inhibition is associated with IFN-signaling in ER+ and endocrine-resistant derivative BC cell lines. Supplementary Figure S3. The cyclin D-CDK4/6-Rb axis is altered in ER+ cell lines with acquired resistance to palbociclib. Supplementary Figure S4. Effect of acute IFN-signaling activation on sensitivity to palbociclib in ER+ BC cell lines. Supplementary Figure S5. Proteomic profiles of MCF7 P, MCF7 EDR, and their PalboR derivatives. Supplementary Figure S6. Relationship between IFN-signaling and Rb status in ER+/HER2- BC. Supplementary Figure S7. DNMT1 mRNA levels in palbociclib-sensitive and PalboR MCF7 and T47D cell lines. Supplementary Figure S8. Mutations of DNA damage response genes are not associated with IFN-signaling in ER+ BC. Supplementary Figure S9. Levels of ER and ER signalling in palbociclib-sensitive and PalboR MCF7 and T47D cell lines. Supplementary Figure S10. HALLMARK gene sets significantly up-regulated in ER+/HER2- BC patients stratified by the status (+/-) of RBsig and IRPS. Supplementary Figure S11. Impact of selected IRPS genes on relapse-free survival of ER+ BC patients.
Supplementary Figure S7 from Comparative Assessment of Diagnostic Homologous Recombination Deficiency–Associated Mutational Signatures in Ovarian Cancer
Authors: Sztupinszki Zsofia , Diossy Miklos , Borcsok Judit , Prosz Aurel , Cornelius Nanna , Kjeldsen Maj K. , Mirza Mansoor R. , Szallasi Zoltan
Published: April 2023

WGS-model, using COSMICv3-weights
Supplementary Data from Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma
Authors: Tuscano Joseph M. , Poh Christina , Kaesberg Paul , Luxardi Guilluame , Merleev Alexander , Marusina Alina , Brunson Ann , Rosenberg Aaron , Jonas Brian , Maverakis Emanual
Published: April 2023

Supplemental Table 4
Supplemental Figure 3 from Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma
Authors: Tuscano Joseph M. , Poh Christina , Kaesberg Paul , Luxardi Guilluame , Merleev Alexander , Marusina Alina , Brunson Ann , Rosenberg Aaron , Jonas Brian , Maverakis Emanual
Published: April 2023

Flow cytometric analysis of NK, NK T cell and Treg subpopulations.
Supplementary Figure from DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
Authors: Kurani Hetakshi , Razavipour Seyedeh Fatemeh , Harikumar Kuzhuvelil B. , Dunworth Matthew , Ewald Andrew J. , Nasir Apsra , Pearson Gray , Van Booven Derek , Zhou Zhiqun , Azzam Diana , Wahlestedt Claes , Slingerland Joyce
Published: April 2023

Supplementary Figure from DOT1L Is a Novel Cancer Stem Cell Target for Triple-Negative Breast Cancer
Supplementary Figure 7 from Spatially Distinct Reprogramming of the Tumor Microenvironment Based On Tumor Invasion in Diffuse-Type Gastric Cancers
Authors: Jeong Hye Young , Ham In-Hye , Lee Sung Hak , Ryu Daeun , Son Sang-Yong , Han Sang-Uk , Kim Tae-Min , Hur Hoon
Published: April 2023

Cytotoxic T cell (CTL) subclusters
Supplementary Figure 5 from Spatially Distinct Reprogramming of the Tumor Microenvironment Based On Tumor Invasion in Diffuse-Type Gastric Cancers
Authors: Jeong Hye Young , Ham In-Hye , Lee Sung Hak , Ryu Daeun , Son Sang-Yong , Han Sang-Uk , Kim Tae-Min , Hur Hoon
Published: April 2023

Functional enrichment analysis of fibroblast subclusters
Supplementary Table S1 from Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response
Authors: Yebra Mayra , Bhargava Shruti , Kumar Avi , Burgoyne Adam M. , Tang Chih-Min , Yoon Hyunho , Banerjee Sudeep , Aguilera Joseph , Cordes Thekla , Sheth Vipul , Noh Sangkyu , Ustoy Rowan , Li Sam , Advani Sunil J. , Corless Christopher L. , Heinrich Michael C. , Kurzrock Razelle , Lippman Scott M. , Fanta Paul T. , Harismendy Olivier , Metallo Christian , Sicklick Jason K.
Published: April 2023

Supplementary Table S1. Short Tandem Repeat (STR) Loci of mSDH GIST models.
Supplementary Figure S4 from Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response
Authors: Yebra Mayra , Bhargava Shruti , Kumar Avi , Burgoyne Adam M. , Tang Chih-Min , Yoon Hyunho , Banerjee Sudeep , Aguilera Joseph , Cordes Thekla , Sheth Vipul , Noh Sangkyu , Ustoy Rowan , Li Sam , Advani Sunil J. , Corless Christopher L. , Heinrich Michael C. , Kurzrock Razelle , Lippman Scott M. , Fanta Paul T. , Harismendy Olivier , Metallo Christian , Sicklick Jason K.
Published: April 2023

Fig. S4. Response of GIST KIT mutant cells to TKI inhibitors A-B. Cell viability of SDH-wildtype (or KIT mutant) GIST cells (GIST-T1 and GIST882 cells) after treatment with imatinib (A) and sunitinib (B) at 72 h as measured by MTT viability assay. Percentage viability, relative to the control wells is plotted.
Supplementary Figure 13 from Spatially Distinct Reprogramming of the Tumor Microenvironment Based On Tumor Invasion in Diffuse-Type Gastric Cancers
Authors: Jeong Hye Young , Ham In-Hye , Lee Sung Hak , Ryu Daeun , Son Sang-Yong , Han Sang-Uk , Kim Tae-Min , Hur Hoon
Published: April 2023

Expression of CCR10 and CCL2 mRNA in The Cancer Genome Atlas (TCGA) stomach adenocarcinoma (STAD) and Samsung medical centre (SMC) cohorts
Supplementary Figure S2 from Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response
Authors: Yebra Mayra , Bhargava Shruti , Kumar Avi , Burgoyne Adam M. , Tang Chih-Min , Yoon Hyunho , Banerjee Sudeep , Aguilera Joseph , Cordes Thekla , Sheth Vipul , Noh Sangkyu , Ustoy Rowan , Li Sam , Advani Sunil J. , Corless Christopher L. , Heinrich Michael C. , Kurzrock Razelle , Lippman Scott M. , Fanta Paul T. , Harismendy Olivier , Metallo Christian , Sicklick Jason K.
Published: April 2023

Fig. S2. Recapitulation of metabolic characteristics of parental tumors and SDH-deficiency by patient-derived mSDH GIST models. A. Concentration of succinate in wildtype (WT) (n = 2), mSDHA (n = 1), mSDHB (n = 3), and mSDHC (n = 1) patient plasma. B. Ratio of succinate to fumarate in WT (n = 2), mSDHA (n = 1), mSDHB (n = 3), and mSDHC (n = 1) patient plasma. C. Percent labeling of M3 pyruvate from [U-13C5] glucose in mSDH GIST models grown for 48 h. D. Percent labeling of M3 lactate from [U-13C5] glucose in mSDH GIST models grown for 48 h. E. Per cell abundance of 2-hydroxyglutarate (2-HG) relative to WT in mSDH GIST models grown for 48 h. One-way ANOVA was performed for statistical analysis with *, P<0.05; ***, P<0.001; ****, P<0.0001. F. mSDH GIST models were treated for 72 h with either DMSO or a 10-point dose range of 2-DG and cell viability was measured using the CellTiter-Glo viability assay. G. mSDH GIST models were treated for 72 h with either DMSO or a 10-point dose range of 6-AN and cell killing was measured using the CellTiter-Glo viability assay.
Figure S5 from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma
Authors: Waldschmidt Johannes M. , Kloeber Jake A. , Anand Praveen , Frede Julia , Kokkalis Antonis , Dimitrova Valeriya , Potdar Sayalee , Nair Monica S. , Vijaykumar Tushara , Im Nam Gyu , Guillaumet-Adkins Amy , Chopra Nitish , Stuart Hannah , Budano Lillian , Sotudeh Noori , Guo Guangwu , Grassberger Clemens , Yee Andrew J. , Laubach Jacob P. , Richardson Paul G. , Anderson Kenneth C. , Raje Noopur S. , Knoechel Birgit , Lohr Jens G.
Published: April 2023

Serial target evaluation in U266 single cell clones undergoing dabrafenib treatment
Figure S4 from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma
Authors: Waldschmidt Johannes M. , Kloeber Jake A. , Anand Praveen , Frede Julia , Kokkalis Antonis , Dimitrova Valeriya , Potdar Sayalee , Nair Monica S. , Vijaykumar Tushara , Im Nam Gyu , Guillaumet-Adkins Amy , Chopra Nitish , Stuart Hannah , Budano Lillian , Sotudeh Noori , Guo Guangwu , Grassberger Clemens , Yee Andrew J. , Laubach Jacob P. , Richardson Paul G. , Anderson Kenneth C. , Raje Noopur S. , Knoechel Birgit , Lohr Jens G.
Published: April 2023

BCL2L11 expression in primary MM cells
Figure S1 from Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma
Authors: Waldschmidt Johannes M. , Kloeber Jake A. , Anand Praveen , Frede Julia , Kokkalis Antonis , Dimitrova Valeriya , Potdar Sayalee , Nair Monica S. , Vijaykumar Tushara , Im Nam Gyu , Guillaumet-Adkins Amy , Chopra Nitish , Stuart Hannah , Budano Lillian , Sotudeh Noori , Guo Guangwu , Grassberger Clemens , Yee Andrew J. , Laubach Jacob P. , Richardson Paul G. , Anderson Kenneth C. , Raje Noopur S. , Knoechel Birgit , Lohr Jens G.
Published: April 2023

Quality parameters of scRNA-seq data before filtering
Supplementary Table S2 from Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors
Authors: Hollebecque Antoine , Chung Hyun C. , de Miguel Maria J. , Italiano Antoine , Machiels Jean-Pascal , Lin Chia-Chi , Dhani Neesha C. , Peeters Marc , Moreno Victor , Su Wu-Chou , Chow Kay Hoong , Galvao Violeta R. , Carlsen Michelle , Yu Danni , Szpurka Anna M. , Zhao Yumin , Schmidt Shelly L. , Gandhi Leena , Xu Xiaojian , Bang Yung-Jue
Published: April 2023

Table S2. Confirmed best overall response per RECIST-1.1 by tumor type
Supplementary Table S1 from Safety and Antitumor Activity of α-PD-L1 Antibody as Monotherapy or in Combination with α-TIM-3 Antibody in Patients with Microsatellite Instability–High/Mismatch Repair–Deficient Tumors
Authors: Hollebecque Antoine , Chung Hyun C. , de Miguel Maria J. , Italiano Antoine , Machiels Jean-Pascal , Lin Chia-Chi , Dhani Neesha C. , Peeters Marc , Moreno Victor , Su Wu-Chou , Chow Kay Hoong , Galvao Violeta R. , Carlsen Michelle , Yu Danni , Szpurka Anna M. , Zhao Yumin , Schmidt Shelly L. , Gandhi Leena , Xu Xiaojian , Bang Yung-Jue
Published: April 2023

Table S1. Prior immunotherapies in anti-PD-1/PD-L1-resistant/refractory cohort
Supplementary Table from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
Authors: Kester Lennart , Seinstra Danielle , van Rossum Annelot G.J. , Vennin Claire , Hoogstraat Marlous , van der Velden Daphne , Opdam Mark , van Werkhoven Erik , Hahn Kerstin , Nederlof Iris , Lips Ester H. , Mandjes Ingrid A.M. , van Leeuwen-Stok A. Elise , Canisius Sander , van Tinteren Harm , Imholz Alex L.T. , Portielje Johanneke E.A. , Bos Monique E.M.M. , Bakker Sandra D. , Rutgers Emiel J. , Horlings Hugo M. , Wesseling Jelle , Voest Emile E. , Wessels Lodewyk F.A. , Kok Marleen , Oosterkamp Hendrika M. , van Oudenaarden Alexander , Linn Sabine C. , van Rheenen Jacco
Published: April 2023

Supplementary Table from Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments
Supplementary Figures SF1-SF9 from Therapeutic Targeting of LIF Overcomes Macrophage-mediated Immunosuppression of the Local Tumor Microenvironment
Authors: Hallett Robin M. , Bonfill-Teixidor Ester , Iurlaro Raffaella , Arias Alexandra , Raman Swetha , Bayliss Peter , Egorova Olga , Neva-Alejo Almudena , McGray AJ Robert , Lau Esther , Bosch Alexandre , Beilschmidt Melissa , Maetzel Dorothea , Fransson Johan , Huber-Ruano Isabel , Anido Judit , Julien Jean-Philippe , Giblin Patricia , Seoane Joan
Published: April 2023

Supplementary Figure 1. Transcriptomic analysis demonstrates an enrichment of immunological pathways in high LIF tumors. Supplementary Figure 2. LIF transcripts are associated with a panel of immunosuppressive macrophage/myeloid signatures across human tumor indications. Supplementary Figure 3. LIF transcripts are specifically associated with suppressive macrophage signatures across human tumor indications. Supplementary Figure 4. LIF transcripts tend to be highly expressed in aggressive tumors. Supplementary Figure 5. LIF drives polarization of immunosuppressive human macrophages. Supplementary Figure 6. RNAseq of LIF induced gene sets in human macrophages predict poor patient outcome and correlate with LIF across human tumor indications. Supplementary Figure 7. Structural analysis of MSC-1 reveals an overlapping epitope with the gp130 binding site and a free cysteine in HCDR3. Supplementary Figure 8. CT26 and MC38 tumors expression LIF protein and monotherapy MSC-1 is well tolerated. Supplementary Figure 9. MSC-1 and anti-PD1 combination is well tolerated and promotes tumor memory in responsive mice.
Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Authors: Shi Zhen , Wulfkuhle Julia , Nowicka Malgorzata , Gallagher Rosa I. , Saura Cristina , Nuciforo Paolo G. , Calvo Isabel , Andersen Jay , Passos-Coelho José Luis , Gil-Gil Miguel J. , Bermejo Begoña , Pratt Debra A. , Ciruelos Eva M. , Villagrasa Patricia , Wongchenko Matthew J. , Petricoin Emanuel F. , Oliveira Mafalda , Isakoff Steven J.
Published: April 2023

Supplementary Figure from Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer
Figure S6 from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
Authors: Delaidelli Alberto , Dunham Christopher , Santi Mariarita , Negri Gian Luca , Triscott Joanna , Zheludkova Olga , Golanov Andrey , Ryzhova Marina , Okonechnikov Konstantin , Schrimpf Daniel , Stichel Damian , Ellison David W. , von Deimling Andreas , Kool Marcel , Pfister Stefan M. , Ramaswamy Vijay , Korshunov Andrey , Taylor Michael D. , Sorensen Poul H.
Published: April 2023

Fig S6. Representative area under the time-dependent receiver operating characteristic (ROC) curves (false positive, FP vs true positive, TP) for overall survival at 3, 6 or 9 years from surgery. Curves are reported for the BH cohort, based on clinical (age, sex, metastasis stage, histology, surgical resection, therapy) + molecular variables (Group 3/4, MYC, MYCN amplification and i17q) (A, p=0.024); clinical variables + molecular subgroups (B, p=0.040); clinical variables only (C, p=0.032); and combined BCCH-CHOP cohort, based on clinical variables (D, p=0.0041).
Figure S4 from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
Authors: Delaidelli Alberto , Dunham Christopher , Santi Mariarita , Negri Gian Luca , Triscott Joanna , Zheludkova Olga , Golanov Andrey , Ryzhova Marina , Okonechnikov Konstantin , Schrimpf Daniel , Stichel Damian , Ellison David W. , von Deimling Andreas , Kool Marcel , Pfister Stefan M. , Ramaswamy Vijay , Korshunov Andrey , Taylor Michael D. , Sorensen Poul H.
Published: April 2023

Fig S4. Overall survival analysis by Kaplan Meier plotting of patients with Group 3/4 medulloblastoma (BH cohort), after stratification based on therapeutic approach and TPD52 IHC. Children in A-B were treated with chemotherapy-only protocols. Patients in C were treated with RT + chemotherapy and in D with therapy intensification. Global p value is reported in the figure. Individual p values (TPD52 neg vs TPD52 => 50%) are as follows: A p=0.0039, B p=0.0079, C p=0.0063, D p=0.020.
Supplementary Table 1 from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials
Authors: Furtner Julia , Weller Michael , Weber Michael , Gorlia Thierry , Nabors Burt , Reardon David A. , Tonn Joerg C. , Stupp Roger , Preusser Matthias
Published: April 2023

Baseline clinical characteristics of all patients by cohort
Figure S2 from Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study
Authors: Delaidelli Alberto , Dunham Christopher , Santi Mariarita , Negri Gian Luca , Triscott Joanna , Zheludkova Olga , Golanov Andrey , Ryzhova Marina , Okonechnikov Konstantin , Schrimpf Daniel , Stichel Damian , Ellison David W. , von Deimling Andreas , Kool Marcel , Pfister Stefan M. , Ramaswamy Vijay , Korshunov Andrey , Taylor Michael D. , Sorensen Poul H.
Published: April 2023

Fig S2. Representative IHC pictures of TMA cores classified as either TDP52 positive or negative. Scale bar = 100 um.
Supplementary Figure 1 from Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials
Authors: Furtner Julia , Weller Michael , Weber Michael , Gorlia Thierry , Nabors Burt , Reardon David A. , Tonn Joerg C. , Stupp Roger , Preusser Matthias
Published: April 2023

CONSORT patient flow chart
Figure S3 from Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
Authors: Harding James J. , Moreno Victor , Bang Yung-Jue , Hong Min Hee , Patnaik Amita , Trigo José , Szpurka Anna M. , Yamamoto Noboru , Doi Toshihiko , Fu Siqing , Calderon Boris , Velez de Mendizabal Nieves , Calvo Emiliano , Yu Danni , Gandhi Leena , Liu Zhuqing Tina , Galvao Violeta Regnier , Leow Ching Ching , de Miguel Maria J.
Published: April 2023

Summary of TIM-3 (A), PD-L1 (B), and CD8 (C) expression at baseline and CD8 expression at baseline and on-treatment in expansion cohorts (D and E).
Figure S2 from Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody
Authors: Harding James J. , Moreno Victor , Bang Yung-Jue , Hong Min Hee , Patnaik Amita , Trigo José , Szpurka Anna M. , Yamamoto Noboru , Doi Toshihiko , Fu Siqing , Calderon Boris , Velez de Mendizabal Nieves , Calvo Emiliano , Yu Danni , Gandhi Leena , Liu Zhuqing Tina , Galvao Violeta Regnier , Leow Ching Ching , de Miguel Maria J.
Published: April 2023

Summary of TIM-3 (A) versus CD8 (B) expression at baseline in expansion cohorts.
Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Authors: Boons Gitta , Vandamme Timon , Mariën Laura , Lybaert Willem , Roeyen Geert , Rondou Tim , Papadimitriou Konstantinos , Janssens Katrien , Op de Beeck Bart , Simoens Marc , Demey Wim , Dero Isabel , Van Camp Guy , Peeters Marc , Op de Beeck Ken
Published: April 2023

Supplementary Data from Longitudinal Copy-Number Alteration Analysis in Plasma Cell-Free DNA of Neuroendocrine Neoplasms is a Novel Specific Biomarker for Diagnosis, Prognosis, and Follow-up
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Authors: Wichmann Jürgen , Rynn Caroline , Friess Thomas , Petrig-Schaffland Jeannine , Kornacker Martin , Handl Cornelia , Emmenegger Jasmin , Eckmann Jan , Herting Frank , Frances Nicolas , Hunziker Daniel , Krummenacher Daniela , Rüttinger Dominik , Ribeiro Alison , Bacac Marina , Brigo Alessandro , Hewings David S. , Dummer Reinhard , Levesque Mitchell P. , Schnetzler Gabriel , Martoglio Bruno , Bischoff James R. , Pettazzoni Piergiorgio
Published: April 2023

Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Authors: Dieci Maria Vittoria , Guarneri Valentina , Tosi Anna , Bisagni Giancarlo , Musolino Antonino , Spazzapan Simon , Moretti Gabriella , Vernaci Grazia Maria , Griguolo Gaia , Giarratano Tommaso , Urso Loredana , Schiavi Francesca , Pinato Claudia , Magni Giovanna , Lo Mele Marcello , De Salvo Gian Luca , Rosato Antonio , Conte Pierfranco
Published: April 2023

Supplementary Data from Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
Supplementary Data from Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
Authors: Rottey Sylvie , Clarke Jeffrey , Aung Kyaw , Machiels Jean-Pascal , Markman Ben , Heinhuis Kimberley M. , Millward Michael , Lolkema Martijn , Patel Sandip Pravin , de Souza Paul , Duca Matteo , Curigliano Giuseppe , Santoro Armando , Koyama Takafumi , Brown Michelle , Vezina Heather , He Chunsheng , Chu Quincy Siu-Chung
Published: April 2023

Supplementary Data from Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors
Supplementary Figure from IL15 and Anti–PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors
Authors: Chen Wei , Bamford Richard N. , Edmondson Elijah F. , Waldmann Thomas A.
Published: April 2023

Supplementary Figure from IL15 and Anti–PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors
Supplementary table 5 from Early HPV ctDNA Kinetics and Imaging Biomarkers Predict Therapeutic Response in p16+ Oropharyngeal Squamous Cell Carcinoma
Authors: Cao Yue , Haring Catherine T. , Brummel Collin , Bhambhani Chandan , Aryal Madhava , Lee Choonik , Heft Neal Molly , Bhangale Apurva , Gu Wenjin , Casper Keith , Malloy Kelly , Sun Yilun , Shuman Andrew , Prince Mark E. , Spector Matthew E. , Chinn Steven , Shah Jennifer , Schonewolf Caitlin , McHugh Jonathan B. , Mills Ryan E. , Tewari Muneesh , Worden Francis P. , Swiecicki Paul L. , Mierzwa Michelle , Brenner J. Chad
Published: April 2023

Detailed summary of HPV16 genome somatic single nucleotide variations identified by targeted capture sequencing analysis of FFPE tumor specimens
Supplementary Table from Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Authors: Grisic Ana-Marija , Xiong Wenyuan , Tanneau Lénaïg , Jönsson Siv , Friberg Lena E. , Karlsson Mats O. , Dai Haiqing , Zheng Jenny , Girard Pascal , Khandelwal Akash
Published: April 2023

Supplementary Table from Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
Supplementary Data from Microbiome Analysis of More Than 2,000 NHS Bowel Cancer Screening Programme Samples Shows the Potential to Improve Screening Accuracy
Authors: Young Caroline , Wood Henry M. , Fuentes Balaguer Alba , Bottomley Daniel , Gallop Niall , Wilkinson Lyndsay , Benton Sally C. , Brealey Martin , John Cerin , Burtonwood Carole , Thompson Kelsey N. , Yan Yan , Barrett Jennifer H. , Morris Eva J.A. , Huttenhower Curtis , Quirke Philip
Published: April 2023

Supplementary Data
Supplemental Table 1-3 from Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03
Authors: Sheng Xinan , Chen Haige , Hu Bin , Yao Xudong , Liu Ziling , Yao Xin , Guo Hongqian , Hu Yi , Ji Zhigang , Luo Hong , Shi Benkang , Liu Jiyan , Wu Jin , Zhou FangJian , He Zhisong , Fan Jinhai , Wang Weifeng , Feng Hui , Yao Sheng , Keegan Patricia , Huang Yiran , Guo Jun
Published: April 2023

Supplemental Table 1. Grade 3 and above treatment-related adverse events in the study; Supplemental Table 2. Biomarker and subgroup analysis for correlation with clinical efficacy in all 151 patients; Supplemental Table 3. PD-L1 JS311 IHC staining results and clinical efficacy.
Supplementary Table from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
Authors: Regan Daniel P. , Chow Lyndah , Das Sunetra , Haines Laurel , Palmer Eric , Kurihara Jade N. , Coy Jonathan W. , Mathias Alissa , Thamm Douglas H. , Gustafson Daniel L. , Dow Steven W.
Published: April 2023

Supplementary Table from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
Supplementary Figure from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
Authors: Regan Daniel P. , Chow Lyndah , Das Sunetra , Haines Laurel , Palmer Eric , Kurihara Jade N. , Coy Jonathan W. , Mathias Alissa , Thamm Douglas H. , Gustafson Daniel L. , Dow Steven W.
Published: April 2023

Supplementary Figure from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
Supplementary Data from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
Authors: Regan Daniel P. , Chow Lyndah , Das Sunetra , Haines Laurel , Palmer Eric , Kurihara Jade N. , Coy Jonathan W. , Mathias Alissa , Thamm Douglas H. , Gustafson Daniel L. , Dow Steven W.
Published: April 2023

Supplementary Data from Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
Figure S1 from High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9
Authors: Majumder Shounak , Taylor William R. , Foote Patrick H. , Berger Calise K. , Wu Chung Wah , Mahoney Douglas W. , Bamlet William R. , Burger Kelli N. , Postier Neil , de la Fuente Jaime , Doering Karen A. , Lidgard Graham P. , Allawi Hatim T. , Petersen Gloria M. , Chari Suresh T. , Ahlquist David A. , Kisiel John B.
Published: April 2023

Supplemental Figure 1 shows the predicted probability of cancer from the cross-validated MDM rForest model, demonstrating no significant difference in model performance based on tumor size, tumor location, presence of symptoms at the time of diagnosis, or timing of biopsy in relationship to blood draw.
Supplementary Figure from Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Authors: Lassman Andrew B. , Sepúlveda-Sánchez Juan Manuel , Cloughesy Timothy F. , Gil-Gil Miguel J. , Puduvalli Vinay K. , Raizer Jeffrey J. , De Vos Filip Y.F. , Wen Patrick Y. , Butowski Nicholas A. , Clement Paul M.J. , Groves Morris D. , Belda-Iniesta Cristóbal , Giglio Pierre , Soifer Harris S. , Rowsey Steven , Xu Cindy , Avogadri Francesca , Wei Ge , Moran Susan , Roth Patrick
Published: April 2023

Supplementary Figure from Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Table A1: ICD-9-CM Neoplasm Terms for Lung Cancer from Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non–Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations
Authors: Harvey R. Donald , Bruinooge Suanna S. , Chen Li , Garrett-Mayer Elizabeth , Rhodes Whitney , Stepanski Edward , Uldrick Thomas S. , Ison Gwynn , Khozin Sean , Rubinstein Wendy S. , Schenkel Caroline , Miller Robert S. , Komatsoulis George A. , Schilsky Richard L. , Kim Edward S.
Published: April 2023

Tables of ICD9 and ICD10 codes used.
Supplementary Table from Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
Authors: Su Yudong , Luo Bingying , Lu Yao , Wang Daowei , Yan Jie , Zheng Jian , Xiao Jun , Wang Yangyang , Xue Zhenyi , Yin Jie , Chen Peng , Li Long , Zhao Qiang
Published: April 2023

Supplementary Table from Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
Supplementary Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
Authors: Arondekar Bhakti , Duh Mei Sheng , Bhak Rachel H. , DerSarkissian Maral , Huynh Lynn , Wang Kelsey , Wojciehowski John , Wu Melody , Wornson Bryon , Niyazov Alexander , Demetri George D.
Published: April 2023

Supplementary Data from Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
Supplementary Figure from Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
Authors: Su Yudong , Luo Bingying , Lu Yao , Wang Daowei , Yan Jie , Zheng Jian , Xiao Jun , Wang Yangyang , Xue Zhenyi , Yin Jie , Chen Peng , Li Long , Zhao Qiang
Published: April 2023

Supplementary Figure from Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
Supplementary Data from Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
Authors: Vincenzi Bruno , Napolitano Andrea , Fiocco Marta , Mir Olivier , Rutkowski Piotr , Blay Jean-Yves , Reichardt Peter , Joensuu Heikki , Fumagalli Elena , Gennatas Spyridon , Hindi Nadia , Nannini Margherita , Spalato Ceruso Mariella , Italiano Antoine , Grignani Giovanni , Brunello Antonella , Gasperoni Silvia , De Pas Tommaso , Badalamenti Giuseppe , Pantaleo Maria A. , van Houdt Winan J. , IJzerman Nikki S. , Steeghs Neeltje , Gelderblom Hans , Desar Ingrid M.E. , Falkenhorst Johanna , Silletta Marianna , Sbaraglia Marta , Tonini Giuseppe , Martin-Broto Javier , Hohenberger Peter , Le Cesne Axel , Jones Robin L. , Dei Tos Angelo P. , Gronchi Alessandro , Bauer Sebastian , Casali Paolo G.
Published: April 2023

Supplementary Data from Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
Supplementary Table S5 from A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Authors: Beinat Corinne , Patel Chirag B. , Haywood Tom , Murty Surya , Naya Lewis , Castillo Jessa B. , Reyes Samantha T. , Phillips Megan , Buccino Pablo , Shen Bin , Park Jun Hyung , Koran Mary Ellen I. , Alam Israt S. , James Michelle L. , Holley Dawn , Halbert Kim , Gandhi Harsh , He Joy Q. , Granucci Monica , Johnson Eli , Liu Daniel Dan , Uchida Nobuko , Sinha Rahul , Chu Pauline , Born Donald E. , Warnock Geoffrey I. , Weissman Irving , Hayden-Gephart Melanie , Khalighi Mehdi , Massoud Tarik F. , Iagaru Andrei , Davidzon Guido , Thomas Reena , Nagpal Seema , Recht Lawrence D. , Gambhir Sanjiv Sam
Published: April 2023

Hematology laboratory testing results of patients imaged with [18F]DASA-23
Figure S2 from High FGFR1–4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
Authors: Sánchez-Guixé Mònica , Hierro Cinta , Jiménez José , Viaplana Cristina , Villacampa Guillermo , Monelli Erika , Brasó-Maristany Fara , Ogbah Zighereda , Parés Mireia , Guzmán Marta , Grueso Judit , Rodríguez Olga , Oliveira Mafalda , Azaro Analía , Garralda Elena , Tabernero Josep , Casanovas Oriol , Scaltriti Maurizio , Prat Aleix , Dienstmann Rodrigo , Nuciforo Paolo , Saura Cristina , Graupera Mariona , Vivancos Ana , Rodon Jordi , Serra Violeta
Published: April 2023

Supplementary Figure 2. FGFR1-3 protein expression in BC PDXs models. A) Western blot (WB) analysis of FGFR1 and FGFR3 protein expression in PDX models; CAL120 cells were used as positive control for FGFR1 expression. B) Clinical evolution of a refractory metastatic triple negative breast cancer (mTNBC) patient -Pt306-, whose primary tumor harbored a high-level FGFR2amp (CN 21.8) and co-amplification of 11q13 (CN 7.0), assessed by FISH. Pt achieved disease stabilization (SD) lasting 8 months: reduction in lung target lesions (TL, red arrow) and overall decrease in other lung non-target lesions (NTL, red circle). Primary tumor biopsy was available for further molecular characterization with IHC FGFR2. C) IHC images of FGFR2 in PDX models and the primary tumor Bx from Pt306, according to the model/patient response to FGFRi (PD or SD). D) Correlation analysis of FGFR1/2/3 mRNA levels vs. protein levels by WB for FGFR1/3 or IHC for FGFR2. FGFR1/3 were quantified with ImageJ (normalized by tubulin levels) and FGFR2 with QuPath and ImageJ. Statistical test: Pearson correlation coefficient (r2) is shown.
Supplementary Table from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Authors: Toulmonde Maud , Brahmi Mehdi , Giraud Antoine , Chakiba Camille , Bessede Alban , Kind Michèle , Toulza Emilie , Pulido Marina , Albert Sabrina , Guégan Jean-Philippe , Cousin Sophie , Mathoulin-Pelissier Simone , Perret Raul , Croce Sabrina , Blay Jean-Yves , Ray-Coquard Isabelle , Floquet Anne , Italiano Antoine
Published: April 2023

Supplementary Table from Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study
Supplementary Data from Targeting the Ubiquitin–Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer
Authors: Majeed Safa , Aparnathi Mansi K. , Nixon Kevin C.J. , Venkatasubramanian Vidhyasagar , Rahman Fariha , Song Lifang , Weiss Jessica , Barayan Ranya , Sugumar Vijithan , Barghout Samir H. , Pearson Joel D. , Bremner Rod , Schimmer Aaron D. , Tsao Ming S. , Liu Geoffrey , Lok Benjamin H.
Published: April 2023

Supplementary Data from Targeting the Ubiquitin–Proteasome System Using the UBA1 Inhibitor TAK-243 is a Potential Therapeutic Strategy for Small-Cell Lung Cancer
Supplementary Materials and Methods from Transcriptomic Analysis of Laser Capture Microdissected Tumors Reveals Cancer- and Stromal-Specific Molecular Subtypes of Pancreatic Ductal Adenocarcinoma
Authors: Birnbaum David J. , Begg Sebastian K.S. , Finetti Pascal , Vanderburg Charles , Kulkarni Anupriya S. , Neyaz Azfar , Hank Thomas , Tai Eric , Deshpande Vikram , Bertucci François , Birnbaum Daniel , Lillemoe Keith D. , Warshaw Andrew L. , Mino-Kenudson Mari , Fernandez-Del Castillo Carlos , Ting David T. , Liss Andrew S.
Published: April 2023

Detailed methods for sample preparation and RNA seqeucning
Supplementary Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
Authors: Tan Antoinette R. , Wright Gail S. , Thummala Anu R. , Danso Michael A. , Popovic Lazar , Pluard Timothy J. , Han Hyo S. , Vojnović Željko , Vasev Nikola , Ma Ling , Richards Donald A. , Wilks Sharon T. , Milenković Dušan , Xiao Jie , Sorrentino Jessica , Horton Janet , O'Shaughnessy Joyce
Published: April 2023

Supplementary Data from Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial
Authors: Zhao Jimmy L. , Fizazi Karim , Saad Fred , Chi Kim N. , Taplin Mary-Ellen , Sternberg Cora N. , Armstrong Andrew J. , de Bono Johann S. , Duggan William T. , Scher Howard I.
Published: April 2023

Supplementary Figure from The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial
Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
Authors: Dziadziuszko Rafal , Peters Solange , Mok Tony , Camidge D. Ross , Gadgeel Shirish M. , Ou Sai-Hong Ignatius , Konopa Krzysztof , Noé Johannes , Nowicka Malgorzata , Bordogna Walter , Morcos Peter N. , Smoljanovic Vlatka , Shaw Alice T.
Published: April 2023

Supplementary Figure from Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non–small Cell Lung Cancer in the Global Phase III ALEX Trial
Supplementary Table 3 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Authors: Liang Yi , Jeganathan Sujeeve , Marastoni Stefano , Sharp Adam , Figueiredo Ines , Marcellus Richard , Mawson Amanda , Shalev Zvi , Pesic Aleksandra , Sweet Joan , Guo Haiyang , Uehling David , Gurel Bora , Neeb Antje , He Housheng Hansen , Montgomery Bruce , Koritzinsky Marianne , Oakes Samantha , de Bono Johann S. , Gleave Martin , Zoubeidi Amina , Wouters Bradly G. , Joshua Anthony M.
Published: April 2023

Compound full list of two libraries
Supplementary Table 2 from Emergence of Enzalutamide Resistance in Prostate Cancer is Associated with BCL-2 and IKKB Dependencies
Authors: Liang Yi , Jeganathan Sujeeve , Marastoni Stefano , Sharp Adam , Figueiredo Ines , Marcellus Richard , Mawson Amanda , Shalev Zvi , Pesic Aleksandra , Sweet Joan , Guo Haiyang , Uehling David , Gurel Bora , Neeb Antje , He Housheng Hansen , Montgomery Bruce , Koritzinsky Marianne , Oakes Samantha , de Bono Johann S. , Gleave Martin , Zoubeidi Amina , Wouters Bradly G. , Joshua Anthony M.
Published: April 2023

List of primers used for qPCR analyses
Supplementary Figure from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial
Authors: Barlesi Fabrice , Tomasini Pascale , Karimi Maryam , Michiels Stefan , Raimbourg Judith , Daniel Catherine , Janicot Henri , Madroszyk Anne , Audigier-Valette Clarisse , Quoix Elisabeth , Mazieres Julien , Moro-Sibilot Denis , Dansin Eric , Molinier Olivier , Morel Hugues , Pichon Eric , Cortot Alexis , Otto Josiane , Chomy François , Souquet Pierre-Jean , Cloarec Nicolas , Giroux-Leprieur Etienne , Bieche Ivan , Lacroix Ludovic , Boyault Sandrine , Attignon Valery , Soubeyran Isabelle , Morel Alain , Tran-Dien Alicia , Jacquet Alexandra , Dall'Olio Filippo Gustavo , Jimenez Marta , Soria Jean-Charles , Besse Benjamin
Published: April 2023

Supplementary Figure from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial
Supplementary Table from Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
Authors: Zhang Wen , Gong Caifeng , Peng Xuenan , Bi Xinyu , Sun Yongkun , Zhou Jianguo , Wu Fan , Zeng Huiying , Wang Yan , Zhou Hui , Zhao Hong , Cai Jianqiang , Zhou Aiping
Published: April 2023

Supplementary Table from Serum Concentration of CD137 and Tumor Infiltration by M1 Macrophages Predict the Response to Sintilimab plus Bevacizumab Biosimilar in Advanced Hepatocellular Carcinoma Patients
Supplementary Table from A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Authors: de Kouchkovsky Ivan , Rao Arpit , Carneiro Benedito A. , Zhang Li , Lewis Catriona , Phone Audrey , Small Eric J. , Friedlander Terence , Fong Lawrence , Paris Pamela L. , Ryan Charles J. , Szmulewitz Russell Z. , Aggarwal Rahul
Published: April 2023

Supplementary Table from A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Supplementary Figure from Large-Scale In Vitro and In Vivo CRISPR-Cas9 Knockout Screens Identify a 16-Gene Fitness Score for Improved Risk Assessment in Acute Myeloid Leukemia
Authors: Jin Peng , Jin Qiqi , Wang Xiaoling , Zhao Ming , Dong Fangyi , Jiang Ge , Li Zeyi , Shen Jie , Zhang Wei , Wu Shishuang , Li Ran , Zhang Yunxiang , Li Xiaoyang , Li Junmin
Published: April 2023

Supplementary Figure from Large-Scale In Vitro and In Vivo CRISPR-Cas9 Knockout Screens Identify a 16-Gene Fitness Score for Improved Risk Assessment in Acute Myeloid Leukemia
Supplementary Figure from Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
Authors: Johannet Paul , Liu Wenke , Fenyo David , Wind-Rotolo Megan , Krogsgaard Michelle , Mehnert Janice M. , Weber Jeffrey S. , Zhong Judy , Osman Iman
Published: April 2023

Supplementary Figure from Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
Supplementary Data from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer
Authors: Bando Hideaki , Tsukada Yuichiro , Inamori Koji , Togashi Yosuke , Koyama Shohei , Kotani Daisuke , Fukuoka Shota , Yuki Satoshi , Komatsu Yoshito , Homma Shigenori , Taketomi Akinobu , Uemura Mamoru , Kato Takeshi , Fukui Makoto , Wakabayashi Masashi , Nakamura Naoki , Kojima Motohiro , Kawachi Hiroshi , Kirsch Richard , Yoshida Tsutomu , Suzuki Yutaka , Sato Akihiro , Nishikawa Hiroyoshi , Ito Masaaki , Yoshino Takayuki
Published: April 2023

Supplementary Data from Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability–High Locally Advanced Rectal Cancer
Supplementary Table from Post-transplant Malignancies Show Reduced T-cell Abundance and Tertiary Lymphoid Structures as Correlates of Impaired Cancer Immunosurveillance
Authors: Datta Rabi R. , Schran Simon , Persa Oana-Diana , Aguilar Claire , Thelen Martin , Lehmann Jonas , Garcia-Marquez Maria A. , Wennhold Kerstin , Preugszat Ella , Zentis Peter , von Bergwelt-Baildon Michael S. , Quaas Alexander , Bruns Christiane J. , Kurschat Christine , Mauch Cornelia , Löser Heike , Stippel Dirk L. , Schlößer Hans A.
Published: April 2023

Supplementary Table from Post-transplant Malignancies Show Reduced T-cell Abundance and Tertiary Lymphoid Structures as Correlates of Impaired Cancer Immunosurveillance